|
|
 |
|
Viewing report
|
|
|
|
Ulcerative Colitis: KOL Insights on Treatment Practices and Unmet Needs
Sociable Pharma, April 2011, Pages: 110
The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. Opinion was also gauged during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
Report highlights:
- Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings
- Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
- Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors
- Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the use of once daily oral dosing formulations for 5-ASAs
- Assesses the impact of the 2011 SUCCESS trial
- Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include adherence to 5-ASA regimens and managing long-term immunosuppression.
Understand key treatment trends:
- The role of biologics in steroid-refractory patients and acute/severe settings
- The use of once daily oral dosing formulations for 5-ASAs
Identify unmet needs:
- Improving adherence to 5-ASA regimens
- Managing patients with severe ulcerative colitis
- Managing long-term immunosuppression
- Optimizing oral corticosteroid therapy
- Initiating anti-TNF therapy in non-acute patients
Key features:
4 treatment maps & 48 treatment settings
- A visual guide to the treatment of Ulcerative Colitis, based on extensive primary and secondary research
Analysis of current US/EU treatment practices involving 5 drug classes
- Corticosteroids, 5-ASAs, immunomodulators, anti-TNF therapies and calcineurin inhibitors
Nine unmet needs identified
- Based on KOL research and meetings at ECCO 2011
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
